Bimekizumab responses in psoriatic arthritis held across joints, skin and nails to three years

Design

Post hoc pooled analysis of two phase 3 trials and open-label extension

Population

1,112 adults with active psoriatic arthritis, biologic-naive or TNFi-experienced

Primary outcome

Response across GRAPPA domains to week 148

Effect

ACR50 54.8%; PASI 100 64.6%; dactylitis resolution 68.6%

A post hoc analysis in Rheumatology, published on 10 October, pooled 1,112 people with psoriatic arthritis treated with bimekizumab 160 mg every four weeks in two phase 3 trials — one in biologic-naive patients, one after TNF inhibitor failure — and their open-label extension.

At three years, 54.8% had an ACR50 response, 59.2% had no swollen joints, 56.6% had resolved enthesitis and 68.6% resolved dactylitis. Complete skin clearance (PASI 100) was seen in 64.6% and nail clearance in 68.0%. Inflammatory bowel disease and uveitis events were rare.

Long open-label extensions retain mainly the patients who are doing well, so these figures describe the best case. The trials were sponsored by the manufacturer.

• Assess all psoriatic arthritis domains — joints, entheses, dactylitis, skin, nails — when judging response.
• Ask about bowel symptoms and eye pain on IL-17 pathway drugs, although events were rare here.
• Expect durable responses in those who respond in the first year.
• Check local availability and cost before discussing bimekizumab.

Why it matters

Psoriatic arthritis affects several domains at once, and durable multi-domain control is the treatment goal.

Don't overread it

A post hoc analysis of an open-label extension; patients who stopped treatment are under-represented.

The statistics, in plain English

Modified non-responder imputation counts dropouts for some reasons as failures, but open-label extensions still tend to flatter long-term results.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.